Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line

被引:10
|
作者
Rhee, MS
Schneider, E
机构
[1] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA
[2] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA
关键词
drug resistance; methotrexate; breast cancer resistance protein; polyglutamylation; folate metabolism;
D O I
10.1016/j.bcp.2004.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Accumulation of methotrexate (MTX) and its polyglutamates (PGs) has been recognized as an important factor in MTX efficacy. We have previously described a multidrug-resistant human breast cancer cell line, MCF7/MX, that exhibits reduced accumulation of total MTX as well as MTX-PGs, and that is resistant to continuous MTX exposure [Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, et al. Methotrexate cross-resistance in a mitoxantrone selected multidrug-resistant MCF7 breast cancer cell line is due to enhanced energy-dependent drug efflux. Cancer Res 2000;60:3514-21]. These cells express high levels of the breast cancer resistance protein (BCRP/ABCG2) that has been shown to actively transport MTX and short-chain MTX-PGs in vitro. However, the effect of BCRP on MTX-PG accumulation in intact cells was unclear. Here, we show that MTX transport by BCRP is required for the observed lower levels of MTX-PGs in the resistant cells. When BCRP was inhibited with fumitremorgin C, or in cells expressing a mutated form of BCRP that is unable to transport MTX, MTX-PG accumulation was similar or even higher than that in the parental cells that do not express BCRP. Concomitantly, there was increased inhibition of thymidylate synthase. It had previously been suggested that BCRP-mediated efflux of MTX-PGs contributed to the reduced MTX-PG accumulation. However, we found no evidence of BCRP-mediated efflux of MTX-PGs from intact cells, suggesting that direct efflux of MTX-PGs does not play a major role in MTX resistance. Together, these data show that BCRP overexpression can cause a reduction in total MTX accumulation as well as a reduction in the proportion of long-chain MTX-PGs. In contrast, BCRP overexpression did not affect natural folate accumulation or the relative distribution of folylpolyglutamates in the resistant, as compared to the parental, cells. Thus, it appears that BCRP overexpression affects the metabolism of the antifolate MTX, but not that of natural folates, although indirect effects cannot be excluded. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 50 条
  • [21] Cobalt Chloride Induces Expression and Function of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Renal Proximal Tubular Epithelial Cell Line HK-2
    Nishihashi, Katsuki
    Kawashima, Kei
    Nomura, Takami
    Urakami-Takebayashi, Yumiko
    Miyazaki, Makoto
    Takano, Mikihisa
    Nagai, Junya
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 40 (01) : 82 - 87
  • [22] Effect of Organic Isothiocyanates on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport
    Yan Ji
    Marilyn E. Morris
    Pharmaceutical Research, 2004, 21 : 2261 - 2269
  • [23] Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport
    Ji, Y
    Morris, ME
    PHARMACEUTICAL RESEARCH, 2004, 21 (12) : 2261 - 2269
  • [24] Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function
    Suvannasankha, A
    Minderman, H
    O'Loughlin, KL
    Nakanishi, T
    Greco, WR
    Ross, DD
    Baer, MR
    LEUKEMIA, 2004, 18 (07) : 1252 - 1257
  • [25] Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function
    A Suvannasankha
    H Minderman
    K L O'Loughlin
    T Nakanishi
    W R Greco
    D D Ross
    M R Baer
    Leukemia, 2004, 18 : 1252 - 1257
  • [26] MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)
    Xuyang Jiao
    Lin Zhao
    Mengtao Ma
    Xuefeng Bai
    Miao He
    Yuanyuan Yan
    Yan Wang
    Qiuchen Chen
    Xinnan Zhao
    Mingyi Zhou
    Zeshi Cui
    Zhihong Zheng
    Enhua Wang
    Minjie Wei
    Breast Cancer Research and Treatment, 2013, 139 : 717 - 730
  • [27] MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)
    Jiao, Xuyang
    Zhao, Lin
    Ma, Mengtao
    Bai, Xuefeng
    He, Miao
    Yan, Yuanyuan
    Wang, Yan
    Chen, Qiuchen
    Zhao, Xinnan
    Zhou, Mingyi
    Cui, Zeshi
    Zheng, Zhihong
    Wang, Enhua
    Wei, Minjie
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 717 - 730
  • [28] Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators
    Kraege, Stefanie
    Koehler, Sebastian C.
    Wiese, Michael
    CHEMMEDCHEM, 2016, 11 (21) : 2422 - 2435
  • [29] The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2)
    Kraege, Stefanie
    Stefan, Katja
    Juvale, Kapil
    Ross, Thomas
    Willmes, Thomas
    Wiese, Michael
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 117 : 212 - 229
  • [30] Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors
    Zhu, Xuezhen
    Wong, Iris L. K.
    Chan, Kin-Fai
    Cui, Jiahua
    Law, Man Chun
    Chong, Tsz Cheung
    Hu, Xuesen
    Chow, Larry M. C.
    Chan, Tak Hang
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (18) : 8578 - 8608